US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help, STAT's Adam Feuerstein writes.

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Constellation Energy rises sharply as Meta Platforms signs an agreement to buy power generation of a Constellation nuclear ...

Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.63M to 6.10M. This put 21.56% of the company's publicly available shares short.

Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean ...

Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent ...